Rank: 29 (Previous rank: 35)
Compare tool: Johnson & Johnson vs. Top 10
CEO: William C. Weldon
Address: 1 Johnson & Johnson Plaza
New Brunswick, NJ 08933
Investors took refuge in Johnson & Johnson during 2008. With almost $64 billion in sales, $13 billion in cash and a diversified product portfolio ranging from drugs to medical devices (not to mention that baby shampoo), J&J is the definition of a "defensive" stock.
On the horizon, J&J faces expiring patents and shrinking markets for some of its big money makers like the Cypher stent for heart disease and its anemia drug Procrit. Expect its drug pipeline to start gushing again in the next year or two, as drugs like Xarelto (to prevent blood clots) wend their way through the FDA approval process. - M.C.
What Readers Say
They speak out on Exxon Mobil and other 500 companies...